Balchem reports record Q1 net sales of $239.7M, adjusted EBITDA up 8%

BALCHEM CORP

2024-Q1 EPS reported $0.89 revenue$239,659,000

Net sales $239.7M (+3.1% YoY), adjusted EBITDA $60.9M (+8.0% YoY), both all-time records.
GAAP EPS $0.89 vs $0.70; adjusted EPS $1.03 vs $0.94 in prior-year quarter.
Human Nutrition & Health segment sales $152.7M (+15.1%), earnings $33.3M (+80.4%).
Cash from operations $33.4M; free cash flow $26.8M for Q1 2024.
VitaCholine became Proud Partner of New York Jets, first sponsorship in nutritional ingredient category.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

BALCHEM CORP reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 3, 2024, Balchem Corporation, reported earnings for the quarter ended March 31, 2024, and certain other information. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

BALCHEM CORP filing history →

Source: SEC EDGAR

accession 0001628280-24-020128

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.